GIANT CELL ARTERITIS (GCA)
Clinical trials for GIANT CELL ARTERITIS (GCA) explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS (GCA) trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS (GCA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to tame giant cell arteritis with fewer steroids
Disease control CompletedThis phase 3 trial tested secukinumab, a biologic drug, in 354 people with giant cell arteritis (GCA), a condition causing inflamed arteries. Participants received either secukinumab or a placebo, along with a steroid taper. The goal was to see if secukinumab could help more peop…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill could tame blood vessel inflammation
Disease control CompletedThis study tested the drug upadacitinib (RINVOQ) in 429 people with giant cell arteritis, a condition causing inflamed blood vessels. Participants took the drug or a placebo along with steroids. The goal was to see if upadacitinib helps achieve remission faster and with less ster…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Which drug protects the heart better in giant cell arteritis?
Knowledge-focused CompletedThis study looked at over 1,600 people with giant cell arteritis, a condition that inflames blood vessels and raises heart risks. Researchers compared tocilizumab and methotrexate to see which better prevents heart attacks, strokes, or death. Using French health data, they analyz…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC